| Title | Human Gene Therapy |
| Abbreviation | Hum. Gene Ther. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Genetics (Q2); Molecular Biology (Q2); Molecular Medicine (Q2) |
| h-index | 159 |
| Overall Rank/Ranking | 3826 |
| SCImago Journal Rank (SJR) | 1.091 |
| Impact Score | 2.95 |
| Publisher | Mary Ann Liebert Inc. |
| Country | United States |
| ISSN | 10430342, 15577422 |
| Best Quartile | Q2 |
| Coverage History | 1990-2023 |
Human Gene Therapy is a journal covering the technologies/fields/categories related to Genetics (Q2); Molecular Biology (Q2); Molecular Medicine (Q2). It is published by Mary Ann Liebert Inc.. The overall rank of Human Gene Therapy is 3826. According to SCImago Journal Rank (SJR), this journal is ranked 1.091. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 159. The best quartile for this journal is Q2.
The ISSN of Human Gene Therapy journal is 10430342, 15577422. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Human Gene Therapy is cited by a total of 1437 articles during the last 3 years (Preceding 2023).
The Impact IF 2023 of Human Gene Therapy is 2.95, which is computed in 2024 as per its definition. Human Gene Therapy IF is increased by a factor of 0.04 and approximate percentage change is 1.37% when compared to preceding year 2022, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2023 of Human Gene Therapy is 2.95. If the same upward trend persists, Impact IF may rise in 2024 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 2.95 |
| 2022 | 2.91 |
| 2021 | 3.56 |
| 2020 | 4.50 |
| 2019 | 3.83 |
| 2018 | 3.37 |
| 2017 | 3.89 |
| 2016 | 3.65 |
| 2015 | 3.72 |
| 2014 | 3.63 |
Human Gene Therapy has an h-index of 159. It means 159 articles of this journal have more than 159 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Human Gene Therapy is 10430342, 15577422. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Human Gene Therapy is 3826. According to SCImago Journal Rank (SJR), this journal is ranked 1.091. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 1.091 |
| 2022 | 1.045 |
| 2021 | 1.163 |
| 2020 | 1.633 |
| 2019 | 1.648 |
| 2018 | 1.731 |
| 2017 | 1.771 |
| 2016 | 1.949 |
| 2015 | 1.739 |
| 2014 | 1.525 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 3826 |
| 2022 | 3923 |
| 2021 | 3215 |
| 2020 | 1953 |
| 2019 | 1881 |
| 2018 | 1760 |
| 2017 | 1713 |
| 2016 | 1467 |
| 2015 | 1850 |
| 2014 | 2241 |
Human Gene Therapy is published by Mary Ann Liebert Inc.. It's publishing house is located in United States. Coverage history of this journal is as following: 1990-2023. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Human Gene Therapy is Hum. Gene Ther.. This abbreviation ('Hum. Gene Ther.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Genetics (Q2); Molecular Biology (Q2); Molecular Medicine (Q2), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Human Gene Therapy latest impact IF is 2.95. It's evaluated in the year 2023. The highest and the lowest impact IF or impact score of this journal are 4.50 (2020) and 2.91 (2022), respectively, in the last 10 years. Moreover, its average IS is 3.6 in the previous 10 years.
The Human Gene Therapy has an SJR (SCImago Journal Rank) of 1.091, according to the latest data. It is computed in the year 2024. In the past 10 years, this journal has recorded a range of SJR, with the highest being 1.949 in 2016 and the lowest being 1.045 in 2022. Furthermore, the average SJR of the Human Gene Therapy over the previous 10-year period stands at 3.6.
The latest h-index of the Human Gene Therapy is 159.
The Human Gene Therapy is published by the Mary Ann Liebert Inc., with its country of publication being the United States.
The Human Gene Therapy is currently ranked 3826 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 10 years, this journal has experienced varying rankings, reaching its highest position of 1467 in 2016 and its lowest position of 3923 in 2022.
The standard ISO4 abbreviation for the Human Gene Therapy is Hum. Gene Ther..
Human Gene Therapy is classified as a journal that the Mary Ann Liebert Inc. publishes.
The Human Gene Therapy encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Human Gene Therapy is assigned the following International Standard Serial Numbers (ISSN): 10430342, 15577422.
The best quartile for the Human Gene Therapy is Q2 (2023).
The Human Gene Therapy coverage history can be summarized as follows: 1990-2023.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| European Union Politics | journal | 2569 | SAGE Publications Ltd | 75 | 3.24 |
| Historia | journal | 28724 | Universidade Estadual Paulista | 8 | 0.02 |
| Revue Francophone des Laboratoires (discontinued) | journal | 23244 | Elsevier Masson s.r.l. | 8 | 0.00 |
| Journal of Supply Chain Management | journal | 587 | Wiley-Blackwell | 112 | 12.51 |
| World Englishes | journal | 3418 | Wiley-Blackwell | 64 | 1.64 |
| International Journal of Parallel, Emergent and Distributed Systems | journal | 16153 | Taylor and Francis Ltd. | 25 | 1.10 |
| Marine Biology Research | journal | 14120 | Taylor and Francis Ltd. | 45 | 1.02 |
| Syntax | journal | 3731 | Wiley-Blackwell Publishing Ltd | 33 | 0.93 |
| Museum Management and Curatorship | journal | 10406 | Routledge | 40 | 1.72 |
| Asian Textile Journal | trade journal | 27997 | G P S Kwatra | 11 | 0.03 |
| Year | Impact Score (IS) |
|---|---|
| 2024/2025 | Coming Soon |
| 2023 | 2.95 |
| 2022 | 2.91 |
| 2021 | 3.56 |
| 2020 | 4.50 |
| 2019 | 3.83 |
| 2018 | 3.37 |
| 2017 | 3.89 |
| 2016 | 3.65 |
| 2015 | 3.72 |
| 2014 | 3.63 |
